Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7881)	11/30/1998 12:27:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Bob, the next DSMB better be ALOT clearer than what you described, at least for me. I will not tolerate any change in trial design or bait and switch job to Hemo. Trauma trial. If efficacy was not enough in Meningo. trial for next DSMB to recommend halt to go for approval I will most likely sell my shares. Also why would DSMB be involved in 90 day follow up if that is the way it goes? After 90 day follow up why does Xoma need a DSMB for Meningo. trial? It seems the least Xoma should do is FULLY explain this DSMB situation especially after saying what they did about possible change in trial design, when trial is supposed to be over. You know Bob, FDA said 2 years, what is all this other about in your attempted answer? Looks to me like a classic setup to switch to Hemo. trauma trial. Only my opinions but I will be watching very closely.